Danske Bank A S lessened its stake in Merck & Co., Inc. (NYSE:MRK – Free Report) by 11.5% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,904,328 shares of the company’s stock after selling 247,694 shares during the quarter. Merck & Co., Inc. makes up about 0.5% of Danske Bank A S’s holdings, making the stock its 28th largest position. Danske Bank A S’s holdings in Merck & Co., Inc. were worth $276,718,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently modified their holdings of the company. BlackRock Inc. raised its position in Merck & Co., Inc. by 0.5% in the 2nd quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock valued at $29,169,479,000 after buying an additional 1,073,507 shares during the last quarter. State Street Corp boosted its holdings in Merck & Co., Inc. by 0.9% during the 2nd quarter. State Street Corp now owns 120,413,256 shares of the company’s stock worth $15,573,754,000 after acquiring an additional 1,087,583 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Merck & Co., Inc. by 2.3% in the 2nd quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock worth $11,083,033,000 after acquiring an additional 1,934,312 shares in the last quarter. Fisher Asset Management LLC grew its stake in shares of Merck & Co., Inc. by 8.3% in the 3rd quarter. Fisher Asset Management LLC now owns 41,699,432 shares of the company’s stock worth $6,059,345,000 after acquiring an additional 3,183,169 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of Merck & Co., Inc. by 10.5% in the first quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock valued at $3,701,831,000 after purchasing an additional 2,919,780 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.
Wall Street Analysts Forecast Growth
Several research analysts have weighed in on the company. Weiss Ratings raised Merck & Co., Inc. from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 25th. Leerink Partners lifted their target price on Merck & Co., Inc. from $127.00 to $161.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 9th. Jefferies Financial Group boosted their price target on shares of Merck & Co., Inc. from $152.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 20th. Wall Street Zen upgraded shares of Merck & Co., Inc. from a “hold” rating to a “strong-buy” rating in a research report on Saturday, November 7th. Finally, Wolfe Research raised their price objective on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the stock an “outperform” rating in a report on Tuesday, August 25th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $155.74.
View Our Latest Analysis on Merck & Co., Inc.
Recent Merck & Co., Inc. Headlines
Investors following MRK have been watching these headlines:
- Positive Sentiment: The EMA’s CHMP recommended expanding ENFLONSIA’s use to help prevent severe RSV lower respiratory tract disease in vulnerable children up to 24 months old, including through their second RSV season. The broader eligible population could support the medicine’s commercial opportunity in Europe. Merck ENFLONSIA CHMP recommendation
- Positive Sentiment: The CHMP also recommended WELIREG plus lenvatinib for adults with advanced clear-cell renal cell carcinoma after anti-PD-1/PD-L1 treatment. This would extend WELIREG into another treatment setting and expand Merck’s oncology portfolio in Europe. Merck WELIREG CHMP recommendation
- Neutral Sentiment: Both decisions are CHMP recommendations; European Commission approval is still needed. Any financial contribution will also depend on launch timing, uptake and competition.
Merck & Co., Inc. Stock Performance
MRK traded up $0.79 during trading hours on Friday, hitting $147.74. The stock had a trading volume of 6,504,320 shares, compared to its average volume of 9,885,298. The company’s fifty day simple moving average is $146.16 and its 200 day simple moving average is $128.61. Merck & Co., Inc. has a 1 year low of $91.49 and a 1 year high of $156.92. The stock has a market cap of $364.21 billion, a PE ratio of 152.31, a price-to-earnings-growth ratio of 6.74 and a beta of 0.13. The company has a quick ratio of 1.14, a current ratio of 1.35 and a debt-to-equity ratio of 1.11.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.09 by $0.40. The business had revenue of $18.09 billion for the quarter, compared to analysts’ expectations of $17.33 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 3.64%. The firm’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period in the previous year, the business posted $2.58 EPS. Equities analysts anticipate that Merck & Co., Inc. will post 2.82 earnings per share for the current year.
About Merck & Co., Inc.
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
Further Reading
- Five stocks we like better than Merck & Co., Inc.
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
- Why Equinix and Digital Realty Benefit From Data Center Zoning Battles
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
